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According to new investigations, oregano oil nasal spray can be used to treat patients with chronic rhinosinusitis (CRS) 
effectively. The current study examines the incremental effect of oregano oil and the use of Persian medicine lifestyle 
modification (PML). 75 adult patients with CRS participated in this study; the clinical trial was done in Otolaryngology 
Clinic of the Fifth Azar Hospital from January 30 to June 25, 2018. A kit including saline bottle, identical PML instruction, 
and identical nasal sprays containing either oregano oil (intervention group), fluticasone (control group) or sesame oil 
(placebo group) was given to all participants for 4 weeks. The reduction of mean change in SNOT-22 scores were 51.52 
(95% CI, -55.79 to -47.24), 21.60 (95% CI, -25.48 to -17.71) and 11.84 (95% CI, -13.18 to -10.51) points for those in the 
oregano, fluticasone and placebo group, respectively. The mean difference of oregano to fluticasone and oregano to placebo 
group were 29.92 (-35.78 to -24.05) to 39.68 (-45.54 to -33.81) point, respectively, in favor of the oregano group. This study 
shows that oregano oil results in clinically meaningful benefits beyond those of fluticasone and sesame oil for patients with 
CRS without nasal polyps. Nonetheless, its generalization should be explored further. 
Keywords: Origanum vulgare, Persian medicine, Sinusitis, SNOT-22 
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CRS is defined as persistent symptomatic 
inflammation of the nasal and sinus mucosa that lasts 
more than 3 months. Epidemiologic studies estimate 
that 10% to 15% of the US population has CRS1 with 
a prevalence of up to 12% in Western populations2. 
CRS is defined as the symptomatic inflammation of 
the nose and paranasalsin uses with the distinction 
based on the duration of the complaints3,4. CRS is 
typically described more broadly as an inflammatory 
disorder and the importance of specific microbial 
agents in driving the process remains controversial. It 
is not clear what medical therapy should be followed 
as the proper treatment for CRS. The most common 
treatment of CRS include medical therapy and in 
cases resistant to medication, endoscopic sinus 
surgery might be an option4.  
CRS is mostly treated by antibiotics and intranasal 
steroids but due to limited evidence, results of 
treatment are unsatisfactory. Previous studies have not 
confirmed the efficiency of herbal medicine to treat 
rhinosinusitis, particularly in chronic cases. New 
investigations recommend that some herbal 
medicines, either alone or combined with other kinds 
of treatment might alleviate the symptoms of severe 
sinus infection5. Several trials reported that certain 
herbal medicines, either alone or combined with other 
kinds of treatment, might treat CRS effectively6.  
Oregano can be used for respiratory tract disorders 
such as bronchitis, cough and asthma, painful 
menstruation, rheumatoid arthritis, dyspepsia and 
urinary tract disorders. Studies have demonstrated the 
pharmacological effects of O. vulgare, including its 
antibacterial and antifungal activity, which is thought 
to be mainly due to the presence of carvacrol (3.5%), 
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thymol (11.6%), terpinen-4-ol (24.90%) and gamma 
terpinen (10.57%) in oreganoessential oil7-9. 
Seemingly, oregano could be a significant source of 
bioactive natural products (essential oil, extracts, or 
pure compounds). Some preclinical (in vitro and in 
vivo) studies argued that oregano could be potentially 
used as a protective agent in chronic-degenerative and 
infectious disease since its bioactive phytochemicals 
shows anticancer, anti-inflammatory, antioxidant and 
antimicrobial activities10-12.CRS pathogenesis is best 
defined as a dysfunctional interaction that happen at 
the site of the connection between the host and the 
environment. In other words, a dysfunctional immune 
response to exogenous factors at the Sino-nasal 
mucosal border leads to mucosal inflammation, 
radiographic changes and symptoms that characterize 
CRS13,14. Immune system modulation is a change in 
the immune response that includes expression, 
induction, or inhibiting each step of the immune 
response15,16. Despite the well-proven effects of 
oregano, a clinical study of sinusitis has not been 
conducted. In the present study, we evaluated the 
influence of oregano oil spray for the treatment of 
CRS without nasal polyps as compared with 
fluticasone and sesame oil spray.  
 
Materials and methods  
The present study is a randomized, double blind, 
clinical trial with participants suffering from sinusitis 
for at least 3 months before the enrollment in the 
study and a clinical diagnosis of CRS without nasal 
polyps.Patientswith a diagnosis of CRS (presenting 
with two major criteria or one major and two minor 
criteria lasting for at least 12 weeks) were recruited 
from the Otolaryngology clinic of the Fifth Azar 
Hospital in Golestan University of Medical Science in 
Gorgan, Iran. The major criteria were purulent 
anterior/posterior nasal discharge, nasal obstruction, 
facial pain/pressure, hyposmia/anosmia and fever 
(acute rhinosinusitis only). The minor symptoms were 
headache, fever (non-acute), halitosis, dental pain, ear 
pain/pressure, cough and fatigue. 
A diagnosis of CRS was confirmed by Coronal 
sinus CT scans. The scans were taken during a 
screening visit and was assessed from serial images 
on coronal and axial views. A Lund-Mackay CT score 
of 5 or more were considered as a diagnostic Imaging 
for CRS. 
Patients within the age range of 18 to 60 years 
meeting the inclusion criteria took part in the study 
after signing the written informed consent. These 
criteria followed the European article on 
rhinosinusitis and nasal polyps 2012 (EPOS 
2012).Patients were willing to use the medication and 
comply with all study guidelines. Inclusion and 
exclusion criteria are listed in Table1. 
 
Ethical approval 
This study was approved by the Ethics Committee 
of Golestan University of Medical Sciences 
(ir.goums.rec.1396. 241).The participants were 
briefed on the study objectives and they signed 
informed consent forms. The study also has been 
registered with the Iranian Clinical Trials Registry 
(no. IRCT20161022030439N2). 
 
Table 1 — Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
1- Between 18 and 60 years old. 
2- Patients signed informed consent. 
3- Positive CT findings (Lund-Mackay CT score 
of 5 or more) 
4- A diagnosis of CRS without nasal polyps 
(CRSsNP) according to EPOS 2012. 
Subjective symptoms: presence of ≥2 
symptoms, 1 of which should be either nasal 
blockage/obstruction/congestion or nasal 
discharge (anterior/posterior nasal drip): 
with/without facial pain/pressure and 
with/without reduction or loss of smell, for 
>12 weeks. Image: Positive CT findings 
(Lund-Mackay CT score of 5 or more). 
 
 
 
1- Treated with other CRS medications 4 weeks before inclusion, such as
steroids or macrolides, or another treatment, such as nasal lavage. 
2- Any one of the following diseases: Gross immunodeficiency (congenital
or acquired); congenital mucociliary problems (eg, primary ciliary 
dyskinesia); cystic fibrosis, based on positive sweat test; systemic
vasculitis and granulomatous diseases; cocaine abuse; or neoplasia. 
3- Patients who underwent sinonasal surgery less than5 years ago. 
4- Patients who had moderate to severe asthma, and acute attack less than
30 days ago. 
5- Aspirin-exacerbated respiratory disease. 
6- Presence of nasal polyps. 
7- Severe systemic diseases affecting cerebrovascular, cardiovascular,
hematologic, neurologic, immunologic, metabolic, or respiratory
systems, with history of psychiatric disease or mental problems. 
8- Participation in other clinical research within latest 30 days. 
9- Pregnant or breastfeeding females. 
10- Patients with acute bacterial sinusitis, (fever≥38.5). 
11- Drug hypersensitivity reaction. 
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Herbal medicinal product  
The herbal medicine applied in this study was 
oregano (O. Vulgare L.). The aerial parts of oregano 
were collected from the Ziarat mountainous region 
in Golestan province at approximately 900 m amsl 
(during the flowering period in July 2017). They 
were identified by Dr Masomeh Mazandrani and a 
voucher specimen was deposited in herbarium of the 
Research Center of Medicinal Plants at Islamic Azad 
University of Gorgan (voucher specimen no. 1613). 
 
Characteristics of herbal product 
The pharmacological treatment of sinusitis and 
decoction preparation in the medieval period was 
gathered from the major Persian pharmaceutical 
manuscripts of Qarabadin-e-Kabir by Aghili Shirazi 
in 1772AD17 and Qarabadin-e-Salehi by Heravi 1765 
AD18. In the present study, a Clevenger-type 
apparatus was used for extraction. This is a modified 
version of the traditional direct heat method.  
The medicinal part of the plant is an aqueous 
extract from the dried leaves produced by steam 
distillation. For preparation, 150 g of oregano leaves 
and 900 mL of water were put in a Clevenger-type 
apparatus (2.5 L balloon) for 1 h, the essential oil was 
dried over anhydrous sodium sulfate and stored in 
dark-colored glass bottles at ±4°C until use. After 
removing the leaves from the water in the balloon, the 
remaining water (oregano aqueous extract) was boiled 
in 150 mL of sesame oil (used as vehicle transport for 
oregano oil) for 2 h to let the water to vaporize and 
the oil remain. The essential oil obtained in the first 
stage of the Clevenger-type apparatus was added to 
the oil obtained in the second step to prepare the final 
product (as oregano oil). 
 
Interventions 
The participants were randomized to either the 
oregano oil (intervention group), fluticasone (control 
group) or sesame oil (placebo group). All study 
participants were provided with a 4-week supply of 
commercial pharmaceutical preparation, a saline 
bottle (Sina-Darou; Iran) and PML. The oregano 
group participants were provided with a supply of 
oregano oil inhaler (16 mg/dose) and the fluticasone 
and sesame groups were provided with supplies of a 
fluticasone inhaler (50 µg/dose) (Sina-Darou; Iran) or 
sesame oil (0.1 mL/dose) (Barij Essence; Iran), 
respectively. The spray bottles for the treatment and 
controlled groups were of similar size, shape and 
color (Sina Darou). All patients performed nasal 
irrigation (240 mL) with normal saline in both 
nostrils. The oregano and sesame groups then applied 
either oregano oil or sesame oil (0.1 mL) nasal spray 
to each nostril, respectively. the oregano group 
received 1 spray of oregano oil (64 mg/day) and the 
fluticasone group received 1 spray of fluticasone 
propionate 0.05% (200 µg/day), while participants  
in sesame group received 1 spray of sesame oil  
(0.4 mL/day). All groups continued their designated 
treatments twice daily for 4 weeks. PML for 
rhinosinusit is comprised: avoiding sleeping in a 
supine position; avoiding exposure to cool weather; 
avoiding nasal irritation and sneezing at the beginning 
of therapy; avoiding intense physical activity; 
reducing consumption of garlic, radishes, celery, 
mustard and onions; use of laxatives such as carrots, 
currants; reduced daytime sleep; reinforcing the brain 
by inhaling rose, apple and saffron aromas; reducing 
food intake; reducing beverages; keeping the head 
warm and covered; and foot massage19-21.  
Compliance to take medication and evaluations for 
undesirable effects was logged at each weekly visit. 
Noncompliance was defined by not taking 
medication less than 5 days in a week as self-reported 
by the patient. Primary and secondary outcomes were 
measured at baseline and 4 weeks post treatment. 
 
Outcomes 
The primary outcome measure was intra-
participant change, pre-treatment to post-treatment, on 
VAS and SNOT-22 scores between the oregano group 
compared with the fluticasone and sesame groups. 
Subjective symptoms were accessed by VAS with 
scores from 0 (no symptom) to 10 (most troublesome) 
and the following 5 nasal symptoms were measured 
for nasal blockage, rhinorrhea, headache, facial pain 
and anosmia.  
The rhinosinusitis-specific scale, the 22-item Sino-
Nasal Outcome Test (SNOT-22)22was used for 
measuring quality of life. Each item is categorized 
into6 levels (0 for no problem to 5 for the problem is 
as bad as it can be). The totalscore is gained by 
adding the score of each item (range 0-110) with 
lower scores implying a better health-related quality 
of life. The reliability and validity of SNOT-22have 
been established in Iranian patients23. It covers a 
widerange of health-related quality of life that may 
affect patient outcomes24. SNOT subscales include 5 
questions on rhinological symptoms, 4 questions on 
ear/facial symptoms, 3 questions on sleep function 
and 6 questions on psychological function. As with 
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the total SNOT scale, higher scores indicate worse 
symptoms and lowerquality of life22. 
The patient reported response to treatment 
measured by major and minor criteria scores was 
considered as secondary outcome measure. 
 
Oregano analysis 
The qualitative analysis of the oregano essential oil 
and oregano oil were processed by GC/MS analysis 
performed with an Agilent 7890A GC system and 
their relative percentages of various components in 
the samples were obtained. The major components 
(area %) of oregano essential oil and oregano oil 
were: p- cymene (11.7%-26.48%), γ-terpinene 
(12.78%-23.02%), terpinen-4-ol (6.01%-4.72%), β-
ocymene (18.52%-13.47%) and thymol (4.78%-
2.81%), respectively. 
 
Safety and tolerability 
Oregano was well tolerated by study participants. 
No major adverse events were reported during the 
trial, except one patient in the fluticasone group 
reporting mild nasal dryness. 
 
Data collection 
Descriptive characteristics, including 
demographics, SNOT-22 questionnaire, VAS score, 
major and minor criteria score were recordedat 
baseline and postintervention. Following 4 weeks of 
treatment, participants returned to the clinic again for 
assessment and SNOT-22 questionnaire, VAS score, 
major and minor criteria score in analogous fashion.  
 
Sample size 
The preliminary data reported by Vazifehkah et al. 
was used for estimating the sample size26. Using a 2-
sided α of 0.05 with 80% power, confidence level of 
0.95 and the effect size of 10.44, it was estimated that 
a sample size of 27 participants per group (total n=81) 
would be required. Considering the limited number of 
eligible patients (N=100) and by applying a sample 
size formula in a finite population, it was estimated 
that a sample size of 25 participants per group (total 
n=75) would be needed. 
 
Randomization 
The patients were assigned to the codes by the 
research coordinator (DA) who saved the allocated 
codes. To conceal the allocation, a unique code was 
assigned to each patient by research coordinator after 
eligibility screening. This code was linked with a 
computer-generated randomization schedule done in 
blocks of 6. Study researchers, attending care teams, 
and patients were blinded to treatment allocation. The 
study evaluations were done with no knowledge of the 
allocation and the research coordinator was excluded 
from evaluation or investigation. The study statistician 
(DB) generated a randomized block design and then 
participants were put into the treatment, control, or 
placebo groups by the study coordinator after 
enrollment. Based on randomization, the patients were 
put into 3 groups of 25 and all participants were 
provided with verbal and written directives to take the 
medications and follow PML appropriately.  
 
Statistical analysis 
The demographic and clinical features and 
evaluations of the study population were summarized 
using descriptive statistics. The effect size was 
measured as the pre-treatment to post-treatment 
change in SNOT-22, VAS and the major and minor 
criteria scores. Normality of data was confirmed by 
Shapiro-Wilk test and homogeneity of variances was 
confirmed with Levene's Test (for Equality of 
Variances). ANOVA and Scheffé analysis was used 
to compare means between groups. All statistical 
analyses was performed with G*Power 3.1.9.2 and R 
software, 3.3.2 (27). Effect size and 95% CIs around 
the effect size have been reported. 
 
Results 
 
Patient characteristics 
A total of 140 patients were enrolled between 
January 30 and June 25, 2018. Of those, 65 patients 
were not eligible for the study. The remaining 75 
patients were randomized to either the oregano 
(n=25), fluticasone (n=25) or placebo (n=25) groups. 
None of the participants withdrew after intervention 
and 75 completed the post- intervention assessments. 
The mean (SD) age was 40.80 (10.79) years and most 
participants were women (n=41; 54.7%). There were 
no significant difference between treatment groups  
in the distribution of baseline demographic 
characteristics, SNOT-22 and VAS scores. 
Demographics and baseline information about all 
participants are shown in Table 2. 
 
Treatment outcomes 
All symptom scores decreased significantly after 
the end of treatment among the three groups. After 4-
weeks of medication, all SNOT-22 scores had 
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decreased markedly and this reduction was 
significantly greater in the oregano group. The mean 
(SD) pre-intervention SNOT-22 score in the oregano 
group was 57.32 (12.35), while reduction in the mean 
(SD) post-intervention score was 5.80 (3.10). Quality 
of life improved in all treatment arms according to 
SNOT-22 after treatment.The mean change and effect 
size in SNOT-22 scores pre-treatment to post-
treatment in the oregano group was (95% CI, -55.79 
to -47.24) and 4.62, respectively; thus, quality of life 
measures of CRS was significantly improved from a 
clinical standpoint.In addition, the VAS scores for all 
symptoms decreased markedly, so the reduction of 
mean change in VAS scores were 27.96 (95% CI, -
31.41 to -24.51), 12.64 (95% CI, -15.38 to -9.89) and 
-5.16 (95% CI, -6.20 to -4.12) points for those in the 
oregano, fluticasone and placebo group, respectively, 
in favor of the oregano group. There was a significant 
decrease in VAS scores in oregano group, so the 
mean (SD) pre-intervention VAS score was 30.76 
(9.13) and the mean (SD) post-intervention score was 
2.80 (2.93), resulted insignificant improvement in 
overall symptomatology (Effect size= 3.46, 95% CI, -
31.41 to -24.51).The mean difference in SNOT-22 
scores for participants in the oregano compared with 
fluticasone group was 29.92 in favor of the oregano 
group (95% CI, -35.78 to -24.05). Moreover, the 
mean difference in SNOT-22 scores for participants in 
the oregano compared with placebo group was 39.68 
in favor of the oregano group (95% CI, -45.54 to -
33.81), which represents a statistically significant 
difference. 
The mean (SD) change in VAS scores from pre-
treatment to post-treatment was 27.96 (8.36) for 
participants in the oregano group and 12.64 (6.65) 
for those in the fluticasone group, for a mean 
difference in score of 15.32 in favor of the oregano 
group (95% CI, -19.80 to -10.83). The mean 
difference in changes in the major and minor criteria 
scores from pre-treatment to post-treatment scores 
was 5.6 (95% CI, -7.60 to -3.60) and 6.28 (95% CI, -
7.88 to -4.68) for the oregano and fluticasone 
groups, respectively, in favor of oregano. The mean 
difference in changes in major and minor criteria 
scores from pre-treatment to post-treatment was 8.3 
(95% CI, -10.30 to -6.31) and 8.48 (95% CI, -10.08 
to -6.88) for the oregano and sesame groups, 
respectively, in favor of the oregano group. A 
decrease of 9 or more in the SNOT-22 score was 
considered clinically meaningful (22). A total of 25 
participants (100%) in the oregano group 
experienced a decrease of 47.24 or more in their 
SNOT-22 scores (95% CI; -55.79 to -47.24), while a 
total of 25 participants (100%) in the fluticasone and 
placebo group experienced a decrease of 17.71 and 
10.51 or more in their SNOT-22 scores (95% CI; -
25.48 to -17.71 and 95% CI; -13.18 to -10.51), 
respectively.The average change of effect size in the 
major criteria scores from pre-treatment to post-
treatment scores was 3.60 (95% CI, 2.33 to 3.16) and 
2.09 (95% CI, 1.11 to 1.58) for the oregano and 
fluticasone groups, respectively, in favor of oregano. 
The average change of effect size in the minor 
criteria scores from pre-treatment to post-treatment 
scores was 4.30 (95% CI, 1.87 to 2.36) and 1.69 
(95% CI, 0.69 to 1.03) for the oregano and 
fluticasone groups, respectively, in favor of oregano. 
The correlation between posttreatment SNOT-22 
score and PML score is -0.453in the oregano group. It 
means that there is an inverse correlation between the 
SNOT-22 score and PML score, as a result, 
significantly better therapeutic outcome in this group. 
The inverse correlation between the SNOT-22 score 
and PML score were observed among the three 
 
Table 2 — Comparison of baseline characteristics between the 3 treatment groups 
Baseline Characteristic Oregano group(n= 25) Fluticasone group(n= 25) Placebo group(n= 25) Effect size 
Age (years), mean ± SD 40.36 (11.17) 42.72 (10.88) 39.32 (10.48) 0.13 
Sex (M/F), n (%) 9/16 (36.0/64.0) 12/13 (48.0/52.0) 13/12 (52.0/48.0) 0.36 
Educational level, n (%)    0.40 
High school 20 (80.0) 20 (80.0) 21 (84.0) 
Bachelor’s degree 4 (16.0) 4 (16.0) 4 (16.0) 
Postgraduate 1 (4.0) 1 (4.0) 0 (0.0) 
SNOT-22 score, mean ± SDa 57.32 ± 12.35 59.20 ± 13.82 60.28 ± 10.33 0.01 
VAS score, mean ± SDa 30.76 ± 9.13 30.92 ± 8.41 35.28 ± 9.09 0.23 
Likert score 57.24 (4.78) 56.64 (5.08) 57.40 (2.96) 0.07 
SD = standard deviation; SNOT-22 = 22-item Sino-Nasal Outcome Test; VAS = visual analog scale. 
SNOT-22 score, (0 = no problem, 1 = very mild problem, 2 = mild or slight problem, 3 = moderate problem, 4 = severe problem, 5 = 
problem as bad as it can be), Likert score= Persian Medicine lifestyle modification 
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groups of this study, as a result, significantly better 
therapeutic outcome in all groups.Table 3 lists the 
effects of treatment within groups and Table 4 lists 
the effects of treatment between groups. 
In this study the patient compliance with nasal 
spray usage were as high as 100% and with PML 
instruction were relatively high (98.53%). We found a 
relatively low compliance with diet recommendations 
of PML in this population (84.8%). 
 
Discussion 
According to the findings of this randomized, 
double-blind, clinical trial, applying oregano oil as a 
daily nasal spray for 4 weeks resulted in a clinically 
meaningful improvement inself-reported functional 
status and quality of life measurements of CRS from a 
clinical standpoint.The upper bound of the confidence 
interval and effect size and lower bound of standard 
deviation suggests that this effect can also be very 
favorable. Oregano was tolerated readily, and 
undesirable adverse effectslinked with its use were 
not reported. 
Oregano is one of the most widely used medicinal 
plants in PM for the treatment of rhinosinusitis28. O. 
vulgareL. has been identified as best candidate for 
modulation of the immune system and 
inflammation29. Oregano extracts canbe used as novel 
options for treatment of chronic diseases involving 
inflammatory processes by increasing the anti-
inflammatory secretions in activated macrophages and 
reducing the release of proinflammatory cytokines30. 
According to experimental studies, oregano can be 
used potentially as a protective agent in chronic-
degenerative and infectious disease since its bioactive 
phytochemicals show anti-inflammatory 
antimicrobial, antioxidant and anticancer features10. 
Natural products containing secondary metabolites 
such as aromatic compounds and terpenoids (essential 
oils) are a good choice for the treatment and 
preventionof chronic infection31. It is known that γ-
terpinene andcarvacrol are natural monoterpenes 
metabolites and their presence in essential oil of 
oregano has been reported to possess strong anti-
inflammatory activity32.Thymoland carvacrol, the two 
main constituents of oregano, contribute to the 
immunomodulatory effect of disorders with immune 
dysregulation. The major components of oregano 
essential oil are carvacrol, thymol and γ –terpinene33. 
Carvacrol decreased the IL-4 content and increased 
the IFN-c and IFN-c/IL4 ratios (Th1/Th2 balance) 
demonstrating the stimulatory effect of carvacrol on 
Th1 and the inhibitory effect on Th2 activity34. 
Thymol is the main component of oregano and 
effectively induces lymphocyte proliferation35 and 
decreases inflammation and wound size36,37.Moreover, 
thymol as a potent antioxidant, protects against cell 
 
Table 3 The within group treatment effect 
Treatment Score Before treatment 
(mean ± SD) 
After treatment 
(mean ± SD) 
(A-B) 
(mean ± SD) 
95% CI of the 
difference 
Effect size 
Oregano SNOT 22 57.32 ± 12.35 5.80 ± 3.10 -51.52 ± 10.36 -55.79 to -47.24  4.62 
Fluticasone SNOT 22 59.20 ± 13.82 37.60 ± 11.04 -21.60 ± 9.41 -25.48 to -17.71  1.70 
Placebo SNOT 22 60.28 ± 10.33 48.44 ± 9.51 -11.84 ± 3.24 -13.18 to -10.51  1.19 
Oregano VAS 30.76 ± 9.13 2.80 ± 2.93 -27.96 ± 8.36 -31.41 to -24.51  3.46 
Fluticasone VAS 30.92 ± 8.41 18.28 ± 6.61 -12.64 ± 6.65 -15.38 to -9.89  1.65 
Placebo VAS 35.28 ± 9.09 30.12 ± 8.28 -5.16 ± 2.53 -6.20 to -4.12  0.59 
 
Table 4 — The between-group treatment effect 
 Oregano and Fluticasone 
(Mean Difference) 
95% CI of the 
difference 
Effect 
size 
Oregano and Sesame 
(Mean Difference) 
95% CI of the 
difference 
Effect 
size 
SNOT-22 score -29.92 -35.78 to -24.05 3.02 -39.68 -45.54 to -33.81 5.16 
VAS score -15.32 -19.80 to -10.83 2.02 -22.8 -27.28 to -18.31 3.69 
Major criteria score -5.6 -7.60 to -3.60 1.72 -8.3 -10.30 to -6.31 2.70 
Minor criteria score -6.28 -7.88 to -4.68 2.48 -8.48 -10.08 to -6.88 3.57 
Rhinological symptoms -10.08 -13.55 to -6.61 1.74 -16.2 -19.67 to -12.37 3.67 
Ear and facial symptoms -4.28 -6.47 to -2.09 1.16 -5.84 -8.03 to -3.65 1.82 
Sleep function  -3.64 -6.02 to -1.26 0.91 -4.12 -6.50 to -1.74 1.15 
Psychological issue -11.92 -15.49 to -8.36 1.96 -13.52 -17.08 to -9.96 2.58 
Rhinological symptoms, Need to blow nose, Sneezing, Runny nose, Nasal obstruction, Loss of smell or taste, Post-nasal discharge, 
Thick nasal discharge; Ear and facial symptoms, Ear fullness, Dizziness, Ear pain, Facial pain/pressure; Sleep function, Difficulty 
falling asleep, waking up at night, Lack of a good night’s sleep; Psychological issues, Waking up tired, Fatigue, Reduced productivity, 
Reduced concentration, Frustrated/restless/irritable, sad, Embarrassed. 
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damage and has useful health effects, such as its anti-
inflammatory, antimicrobial, antioxidant, antiviral, 
anticancer, antispasmodicand growth enhancement 
properties38.Similar results have been found with the 
use of herbal medicine in CRS. Vazifehkah et al. 
compared the effects of Pimpinella anisum-based 
herbal medicine and fluticasone nasal spray for 
treating CRS over a 1-month treatment period in a 
study population. It was concluded that P. anisum-
based herbal medicine may be an effective treatment 
for sinusitis based on the SNOT-22 scores26. The 
mean (SD) change in SNOT-22 scores for participants 
in the sinupim study was 20.80 (16.24; 95% CI, -
14.24 to 27.36). For those in the oregano study, it was 
51.52 (10.36; 95% CI, -47.24 to 55.79) for a mean 
difference of 30.72 in favor of the oregano study. 
Also, Vazifehkah et al found a clinically 
improvement in the mean change in SNOT-22 scores, 
in patients with CRS without nasal polyps treated 
with fluticasone spray group (10.36; 95% CI, 5.79 to 
14.90). In the current trial, a clinically significant 
improvement was observed in the mean change in 
SNOT-22 scores in patients with CRS without nasal 
polyps treated with the fluticasone inhaler group 
(21.60; 95% CI, 17.71 to 25.48), with mean difference 
of 11.24 in favor of our present trial. These results are 
surprising and suggest that our improved treatment 
and better results in our trial may be due to use of 
PML. 
Tait et al. reported a clinically significant 
improvement in SNOT-22 scores in patients with 
CRS treated with budesonide added to large-volume, 
low-pressure saline sinus irrigation39. The mean (SD) 
change in SNOT-22 scores for participants in the 
Budesonide study was 20.7 (17.9) and for those in the 
oregano study, it was 51.2 (10.36) for a mean 
difference of 30.82 in favor of the oregano study. 
Many factors, including the ability of the oregano 
extract and essential oil to stick to the nasal mucosa 
leading to decreased inflammation and modulated 
immune response resulting in the penetration of the 
sinus cavities could explain the advantage of using 
oregano among participants in the current paper. 
 
Limitations 
There were several limitations to this study. First, 
the trial lasted only 4 weeks that may not be adequate 
for producing a thorough effect for oregano 
therapy.Additionally, our patients were all topically 
managed for CRS, which included topical intranasal 
corticosteroids or herbal-based product. However, a 
controlled group of topical intranasal herbal products in 
combination with the oral herbal product should be 
considered, with and without PML. Future research on 
medical outcomes will be needed to determine whether 
or not the treatments have efficacy in these endotypes 
and whether specific markers can be identified that 
predict the response. The current objective measures 
are often nonspecific; thus, future objective measures 
should includepost-treatmentCT scanning, local 
inflammatory cytokine levels or other molecular 
markers characteristics of specific endotypes.  
 
Conclusion 
This study showed that the use of O. vulgare-based 
herbal product resulted in clinically meaningful 
benefits for patients with CRS without nasal polyps. 
Its beneficial effects, availability, safety and low cost 
were remarkable and recommend its use for chronic 
rhinosinusitis. Additional randomized clinical trials 
on the effect of oregano product and PML for those 
with CRS versus the fluticasone-alone controls and, 
oregano-alone versus fluticasone-alone nasal spray 
are needed to help define the true effect of oregano in 
unique patient subgroups. 
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